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Understanding contributors to mortality during the initial phase of tuberculosis (TB) treat-
ment in patients co-infected with HIV would guide targeted interventions to improve survival.
The aim of this study was to ascertain the incidence of death during the initial 2 months
(new cases) and 3 months (retreatment cases) of TB treatment and to assess correlates of
mortality in HIV co-infected patients.
Methods
We conducted a hospital-based retrospective cohort study from January 2006 to December
2013 at Yaoundé Central Hospital, Cameroon. We reviewed medical records to identify co-
infected TB/HIV inpatients aged 15 years and older who died during TB treatment. Death
was defined as any death occurring during TB treatment, as per World Health Organization
recommendations. We collected socio-demographic, clinical and laboratory data. We con-
ducted multivariable logistic binary regression analysis to identify factors associated with
death during the intensive phase of TB treatment. Magnitudes of associations were
expressed by adjusted odds ratio (aOR) with 95% confidence interval. A p value < 0.05 was
considered statistically significant.
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Results
The 99 patients enrolled had a mean age of 39.5 (standard deviation 10.9) years and 53%
were male. Patients were followed for 276.3 person-months of observation (PMO). Forty
nine patients were died during intensive phase of TB treatment. Death incidence during the
intensive phase of TB treatment was 32.2 per 100 PMO. Having a non-AIDS comorbidity
(aOR 2.47, 95%CI 1.22-5.02, p = 0.012), having extra-pulmonary TB (aOR 1.89, 95%CI
1.05-3.43, p = 0.035), and one year increase in duration of known HIV infection (aOR 1.23,
95%CI 1.004-1.49) were independently associated with death during the intensive phase of
TB treatment.
Conclusions
Mortality incidence during intensive phase of TB treatment was high among TB/HIV co-
infected patients during TB treatment; and strongly associated with extra pulmonary TB
suggesting advanced stage of immunosuppression and non-AIDS comorbidities. Early HIV
diagnosis and care and good management of non-comorbidities can reduce this incidence.
Introduction
Tuberculosis (TB) remains the most common serious opportunistic infection in people
infected with human immunodeficiency virus (HIV) in sub-Saharan Africa and is the leading
cause of death [1–5]. In Cameroon, in 2012, the prevalence of HIV infection among adults
aged 15 to 49 years was 4.3%, and the death rate from HIV was 159 per 100,000 people [6]. It is
estimated that 38% of all HIV-infected patients in Cameroon have had active TB at least once
in their lifetime [7]. The mortality rate among those co-infected with TB and HIV was 35 per
100,000 persons [7]. Once active TB is diagnosed, pharmacologic treatment is mandatory and
should be prescribed in a timely manner. TB treatment comprises two consecutive phases: an
initial intensive phase lasting two months for new cases and three months for retreatment
cases, followed by a completion phase using fewer anti-tuberculous medications and lasting
four and five additional months, respectively [8–10]. Prior studies have noted that death in TB/
HIV co-infected patients tends to occur early in the course of TB treatment [11–14]. In Malawi,
factors associated with early death in TB complicating HIV includedMycobacterium tuberculo-
sis bacteremia [15]. Also in Malawi, a study focused on premature deaths in TB patients found
associations with severe malnutrition, age> 35 years, and the presence of HIV co-infection
[16]. A more recent study of TB patients in India [17] determined that increasing age and new
(as compared to recurrent) TB disease were risk factors for early mortality. We are not aware
however, of any study to date designed to investigate why TB/HIV co-infected patients have a
greater mortality during intensive phase of TB treatment in sub-Saharan Africa. In a previous
study [18], we reported low TB treatment success rates and high mortality in a cohort of TB/
HIV co-infected patients in Yaoundé. In the present study, we examine the incidence and
socio-demographic, clinical, and laboratory factors associated with death during intensive
phase of TB treatment in our cohort of TB/HIV co-infected patients. The identification of rele-
vant factors would potentially allow health policy makers and clinicians to make recommenda-
tions to improve the survival of TB/HIV co-infected patients during anti-TB treatment in
resource-limited health care settings.
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Materials and Methods
Design and Population
Our hospital-based retrospective cohort study took place at the Infectious Diseases Unit (IDU)
of the tertiary-care Yaoundé Central Hospital (YCH), in Cameroon. Inpatients aged 15 years
and older diagnosed with TB from January 1, 2006 to June 30, 2013 who were co-infected with
HIV and who died during their TB treatment were included. We excluded all outpatients as
more than 70% of those initiating TB therapy as outpatients had incomplete data. We also
excluded patients who died before initiation of TB treatment or on the date TB treatment
began, cases with missing information on follow-up and missing documentation of outcomes
in the IDU/TB registers, and patients with incomplete file information (at least 30% of vari-
ables). We reviewed a total of 681 TB yellow cards [8], handwritten medical records, and the
TB registry entries of the IDU-YCH. A TB yellow card is an A4 format paper used in the course
of TB treatment. Each yellow card documents a patient’s demographic and administrative
information (name, sex, age, address, TB registry number), along with the type of TB at the
start of treatment (pulmonary versus extra-pulmonary), HIV status, and a calendar with check
boxes for each day anti-TB medications are taken.
Data collection
For new and retreatment cases, we considered the intensive phase as the first two and the initial
three months of anti-tuberculous therapy respectively [8, 10]. Five first-line drugs are used in
Cameroon for initiating treatment of new and retreatment cases of TB: Rifampicin (RIF), Iso-
niazid (INH), Ethambutol (EMB), Pyrazinamide (PZA), and Streptomycin (S) [8]. Irrespective
of HIV status, the treatment of newly diagnosed TB in Cameroon begins with an intensive
phase of a four-drug regimen of INH+RIF+PZA+EMB lasting two months, followed by a two-
drug continuation phase with INH+RIF for four months, for a total of six months of treatment.
Retreatment cases require eight months of therapy, starting with an intensive phase of two
months of five drugs, INH+RIF+PZA+EMB+S followed by one month of INH+RIF+PZA
+EMB, after which the continuation phase consist of five more months of a three-drug regimen
of INH+RIF+EMB [8].
A death for the purposes of this study was defined as a death from any cause during treat-
ment for tuberculosis as per the World Health Organization’s recommendations [9]. All of our
patients were hospitalized for the intensive phase of their TB treatment, resulting in directly
observed treatment (DOT). After the intensive phase patients were permitted to continue their
treatment while residing at home. For those patients who died outside a hospital setting, confir-
mation of death was obtained by phoning the contact person listed in the patient’s medical
record. If it was not possible to reach that contact person to confirm the death, the patient was
considered as lost to follow-up. As described in detail previously [18], we have collected socio-
demographic, clinical, and laboratory data. National recommendations [8] adopted from the
WHO Standard International Definitions [9] were used to classify TB status at the time of diag-
nosis and the type of TB clinical presentation.
Data analysis
Data was extracted, coded, entered, and analyzed using the Statistical Package for Social Sci-
ence (SPSS) version 21.0 for Windows (IBM Corp. Released 2012. IBM SPSS Statistics for Win-
dows, Version 21.0. Armonk, NY: IBM Corp.). Continuous variables were expressed as the
mean with standard deviation (SD) or median with interquartile range (IQR). Categorical vari-
ables were expressed as numbers with percentages (%). Death incidence ratio was analyzed
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using Windows Program for Epidemiologists version 11.25 and reported with Fisher’s exact
95% confidence interval (95%CI). All follow-ups were censored at three months and two
months for retreatment and new cases respectively. This is because the intensive phase of TB
treatment is defined as the first three months of therapy for retreatment of TB and the initial
two months for new TB cases [10].
Multiple imputation was used to handle missing data, creating a new data set, which was the
average of twenty data sets of imputed values imputation [19, 20]. All variables used to search
for risk factors of death and outcome variable (death) were included in the imputation model.
To limit the loss in power to no more than 1% during imputation, we have done 20 imputa-
tions [21]. We have used automatic imputation method without constraints. Continuous and
categorical missing data were imputed by linear regression and logistic regression models
respectively. Fraction of missing information was lower, between 0.002 and 0.158, then chosen
number of imputations were largely adequate [21].
Firstly, we conducted univariate binary logistic regression analysis. After this, we performed
multivariable (including all variables tested in univariate analysis) binary logistic regression
analysis to identify independent predictors of death during intensive phase of TB treatment.
We also performed these univariate and multivariable analyses with categorization of all con-
tinuous data (age, duration of know HIV infection, body weight, white blood cell, hemoglobin
level, CD4 lymphocytes count). A p value< 0.05 was considered statistically significant. Odds
ratios (OR) were reported with a 95%CI.
Ethics statement
We obtained ethical clearance from the Review Board of the Faculty of Medicine and Biomedi-
cal Sciences, University of Yaoundé 1, Cameroon. An administrative authorization of the
Yaoundé Central Hospital was also obtained before data collection. All data were anonymously
collected. Patients’ records and information were anonymized and de-identified prior to
analysis.
Results
Of 337 hospitalized patients, aged 15 years or more with TB who were also HIV positive, we
identified 99 patients who died during TB treatment (Fig 1).
Socio-demographic, clinical and laboratory description of study
population
Table 1 presents the socio-demographic, clinical, and laboratory characteristics of our study
population (n = 99). The mean age was 39.5 years (SD 10.9). Slightly more than half of the
patients were male (n = 52), most had achieved a secondary or tertiary level of higher level of
education (n = 69), nearly two-thirds lived alone (n = 60), and the majority resided in an urban
area (n = 86) of Cameroon. Most of the TB cases had been diagnosed before 2010 (n = 70), had
smear-positive pulmonary TB (n = 41), and represented new cases (n = 88). The mean duration
of known HIV infection was 6.1 years (SD 15.6) and the cohort’s mean body weight was 50.0
kg (SD 11.2). Another AIDS-defining infection (besides TB) was present in 27%; one fifth of
the cohort had non-AIDS medical comorbidities (n = 20). About one third of our cohort was
not taking CPT (n = 32) and not taking ART (n = 36). The median white blood cell count was
4,700 cell/mm3 (IQR 3050–8050), the median CD4 lymphocyte count was 42 cell/mm3 (IQR
15–101), and the median hemoglobin level was 8 g/dl (IQR 6–9).
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Incidence of death during intensive phase of TB treatment
Patients were followed for 276.3 person-months of observation with median duration of 8.1
days (IQR 3.0–24.9) and mean of 20.4 days (SD 27.9). Among the 99 patients who died during
TB treatment, 89 died during the intensive phase of TB treatment. Death incidence during the
intensive phase of TB treatment was 32.2 per 100 persons-months of observation. Fig 2 pres-
ents a Kaplan-Meier survival curve over the course of TB treatment. The slope of the curve is
steepest for the first month and flattens out after the third month, indicating a high rate of
death during the first two months, most notably during the first (Fig 2).
Factors associated with death during intensive phase of TB treatment
In our univariate analysis, two factors associated with death during the intensive phase of TB
treatment were extra-pulmonary TB at presentation (OR 1.84, 95%CI 1.11–3.05, p = 0.018)
and the presence of any non-AIDS comorbidity (OR 1.85, 95%CI 1.07–3.20, p = 0.027). Inde-
pendent factors associated with death during intensive phase of TB treatment were having
non-AIDS comorbidity (aOR 2.47, 95%CI 1.22–5.02, p = 0.012), having extra-pulmonary TB
((aOR 1.89, 95%CI 1.05–3.43, p = 0.035) compared to localized pulmonary TB, and one year
increase in duration of known HIV infection (aOR 1.23, 95%CI 1.004–1.49). These results are
reported in Table 2.
After categorization of all continuous data, in multivariable analysis, having extra-pulmo-
nary TB (adjusted OR 2.19, 95%CI 1.51–4.17, p = 0.017) as compared to localized pulmonary
Fig 1. Enrollment of study participants.
doi:10.1371/journal.pone.0132394.g001
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Table 1. Socio-demographic, clinical, and immunological description of study population.
Variables Death during intensive phase (n = 89) Death after intensive phase (n = 10) All (N = 99)
SOCIO-DEMOGRAPHIC PROFILE
Sex
- Male 47 (53) 5 (50) 52 (53)
- Female 42 (47) 5 (50) 47 (47)
Age, years
- Mean 40.1 (10.8) 34.3 (11.0) 39.5 (10.9)
- Median 38 (33–48) 36 (26–39) 37 (32–48)
Level of education
- Primary/No formal 29 (33) 1 (10) 30 (30)
- Secondary/Tertiary 60 (67) 9 (90) 69 (70)
Marital status
- Alone (single/widowed/ divorced) 53 (60) 7 (70) 60 (61)
- Married/Cohabitating 36 (40) 3 (30) 39 (39)
Residence
- Rural 12 (13) 1 (10) 13 (13)
- Urban 77 (87) 9 (90) 86 (87)
CLINICAL PROFILE
Year of TB diagnosis
- 2006–2009 64 (72) 6 (60) 70 (71)
- 2010–2013 25 (28) 4 (40) 29 (29)
TB clinical presentation*
- Mixed (Pulmonary + EP TB) 6 (7) 2 (20) 8 (8)
- EP TB only 26 (29) 5 (50) 31 (31)
- SNP TB only 17 (19) 2 (20) 19 (19)
- SPP TB only 40 (45) 1 (10) 41 (41)
Status at TB diagnosis
- Retreatment case 11 (12) 0 11 (11)
- New case 78 (88) 10 (100) 88 (89)
Body weightα (Kg)
- Mean 50.0 (11.3) 49.7 (10.7) 50.0 (11.2)
- Median 48 (42–55) 49 (43–59) 48 (42–55)
Duration of known HIV infection, months
- Mean 5.4 (13.9) 12.4 (26.8) 6.1 (15.6)
- Median 0.5 (0.1–3.2) 0.5 (0.1–11.8) 0.5 (0.1–3.6)
Presence of another AIDS-related disease
- Yes 23 (26) 4 (40) 27 (27)
- No 66 (74) 6 (60) 72 (73)
Presence of another non-AIDS comorbidity
- Yes 16 (18) 4 (40) 20 (20)
- No 73 (82) 6 (60) 79 (80)
Cotrimoxazole prophylactic therapy
- No 30 (34) 2 (20) 32 (32)
- Yes 59 (66) 8 (80) 67 (68)
Antiretroviral therapy
- No 33 (37) 3 (30) 36 (36)
- Yes 56 (63) 7 (70) 63 (64)
LABORATORY PROFLE
(Continued)
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TB and having non-AIDS comorbidity (adjusted OR 2.23, 95%CI 1.12–4.46, p = 0.023), was
associated with death during intensive of TB treatment. Duration of known HIV infected was
not associated with early death when is categorized. These results were reported in Table 3.
Discussion
Our study aimed to determine the incidence of death and factors associated with mortality dur-
ing the intensive phase of TB treatment in TB/HIV co-infected inpatients. There was a high
mortality rate during the intensive phase of TB treatment among TB/HIV co- infected patients.
The presence of extra-pulmonary TB at treatment initiation, non-AIDS medical comorbidities,
and increasing duration of known HIV infection were independent risk factors for death.
Our study found a high mortality rate (90%, n = 89) of death during intensive phase of TB
treatment among patients co-infected with TB and HIV. This finding is consistent with other
studies reporting high rates of early death in TB/HIV co-infected people during ongoing TB
treatment [12–14]. As we demonstrated in a recently published study of the IDU-YCH cohort
[18] and in other studies in Africa [14, 22, 23], most patients present at an advanced stage of
immunosuppression. Prescribing ART close to the time of TB treatment initiation in a person
at an advanced stage of immunosuppression can lead to immune reconstitution inflammatory
syndrome (IRIS) [24–27]. It is well established that mortality increases in the setting of IRIS
[25–27]. That fact is a possible explanation for some of the deaths during the intensive initia-
tion phase (early death) of TB treatment in patients infected with HIV. Controversy remains as
to the optimal timing of ART initiation in TB/HIV co-infection. Some studies recommend
early initiation of ART [28, 29]; a more recent prospective randomized trial however, advocates
for delayed ART initiation [30]. As the cause of death was not ascertained in our study we can-
not determine how many patients did in fact have IRIS or IRIS-related mortality.
Our study also reveals that a diagnosis of extra-pulmonary TB at presentation is a risk factor
for death during the intensive phase. Due to the difficultly in diagnosing extra-pulmonary TB
in our resource-limited clinical setting, often compounded by patients’ limited financial
resources that would allow for timely targeted diagnostic testing, such a diagnosis tended to be
made late, at a more advanced stage of disease. Also, extra-pulmonary TB is a marker of more
advanced host immunosuppression, as compared to pulmonary TB that remains confined to
Table 1. (Continued)
Variables Death during intensive phase (n = 89) Death after intensive phase (n = 10) All (N = 99)
White blood cell countβ, cells/mm3
- Mean 6,895 (7,836) 6,168 (4,843) 6,815 (7,551)
- Median 4,700 (3,100–8,000) 4,450 (2,500–10,000) 4,700 (3,050–8,050)
Hemoglobin levelβ, g/dl
- Mean 7.8 (2.5) 8.1 (2.0) 7.8 (2.5)
- Median 8 (6–9) 8 (7–9) 8 (6–9)
CD4 Lymphocytes countβ, cells/mm3
- Mean 71.5 (84.3) 66.0 (71.3) 70.9 (82.7)
- Median 42 (15–97) 29 (14–143) 42 (15–101)
Data are n (%), mean (standard deviation) and median (interquartile range).
* SPP: smear positive pulmonary, SNP: smear negative pulmonary, EP: extra pulmonary.
TB: tuberculosis
α = 9 missing data,
β = 7 missing data
doi:10.1371/journal.pone.0132394.t001
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the respiratory system. The same pathophysiologic process related to increasing immunosup-
pression is invoked as IRIS, which favors death [25–27], occurs mainly at the advanced stage of
immunosuppression [24–27].
The presence of a non-AIDS medical comorbidity was associated with death during the
intensive phase of TB treatment in our study. This is a novel finding. We have not found any
published study implicating this clinical factor in mortality during intensive of TB treatment.
One likely explanation is that comorbidities further compromise the health of TB/HIV co-
infected patients, or their response to the anti-tuberculous medication, or both, thus contribut-
ing to premature death. The care of HIV-infected patients with tuberculosis and non-AIDS
related comorbidities should therefore be carefully initiated as soon as possible, with close
attention to identification and treatment of non-AIDS illnesses. The plan of care especially dur-
ing the intensive phase of anti-tuberculous medication prescription, should also focus on and
address the comorbidity. Identification of patients with this risk factor, and its optimal man-
agement could ameliorate the overall survival of TB/HIV co-infected patients undergoing TB
treatment. Another likely contributor to the increased mortality in patients with a non-AIDS
comorbidity is that the polypharmacy of multiple drugs (non-AIDS comorbidity drugs, plus
Fig 2. Kaplan-Meier survival curve of cumulative survival over time during tuberculosis treatment of patients co-infected with HIV.
doi:10.1371/journal.pone.0132394.g002
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TB drugs and/or ART and CPT), along with the required multidrug antituberculous regimen
could result in less adherence to treatment [31–34], to increased drug-related adverse events,
and to decreases in bioavailability of some drugs [35, 36].
We also found as a factor associated with early death, increasing duration to be known as
HIV-infected. This result was found in another study [37]; and several possible reasons can
explain. Life expectancy may decrease gradually as the duration of infection increases. Patients
who have a long duration of HIV infection develop more resistance to antiretroviral treatment.
Our study has some limitations to consider. It captured patients undergoing treatment for
tuberculosis over a consecutive 90-month period, from January 1, 2006 through June 30, 2013.
The Cameroonian Ministry of Public Health issued new guidelines for prescribing ART in
Table 2. Factors associated with death during the intensive phase of tuberculosis treatment.
Variables Univariate analysis Multivariable analysis
p Odds ratios
(95%CI)
p Adjusted odds ratios
(95%CI)
Sex Male .786 0.94 (0.62–1.43) .707 0.89 (0.49–1.62)
Female 1
Age, years Continuous .241 1.01 (0.99–1.03) .049 1.03 (1.00–1.05
Level of education Primary/No formal .763 1.07 (0.69–1.67) .814 0.94 (0.56–1.57)
Secondary/Tertiary 1
Marital status Alone (single/widowed/ divorced) .913 0.97 (0.64–1.50) .406 1.30 (0.70–2.39)
Married/Cohabitating 1
Area of residence Rural .111 1.65 (0.89–3.04) .109 1.89 (0.87–4.09)
Urban 1
Year of TB diagnosis 2006–2009 .657 1.11 (0.70–1.77) .646 1.15 (0.63–2.10)
2010–2013 1
Clinical presentation* SPP TB only 1
SNP TB only .749 1.11 (0.60–2.04) .265 1.53 (0.73–3.21)
EP TB only .018 1.84 (1.11–3.05) .035 1.89 (1.05–3.43)
Mixed (Pulmonary + EP TB) .644 0.81 (0.33–1.97) .971 1.02 (0.36–2.84)
Status at TB diagnosis New .942 0.98 (0.52–1.84)
Retreatment 1 .449 0.74 (0.34–1.60)
Duration of know HIV infection, years Continuousα .300 0.91 (0.77–1.08) .045 0.81 (0.67–0.996)
Body weight, Kg Continuousα .631 1.01 (0.99–1.02) .795 0.997 (0.98–1.02)
Presence of another AIDS opportunistic infection Yes .196 1.37 (0.85–2.21) .337 1.33 (0.74–2.37)
No 1
Presence of non-AIDS comorbidity Yes .027 1.85 (1.07–3.20) .012 2.47 (1.22–5.02)
No 1
Cotrimoxazole prophylactic therapy Yes 1
No .363 0.81 (0.52–1.27) .629 0.88 (0.52–1.50)
Antiretroviral therapy Yes 1
No .899 1.03 (0.67–1.58) .148 1.48 (0.87–2.53)
White blood cell count, cells/mm3 Continuous .558 1.00 (1.00–1.00) .448 1.00 (1.00–1.00)
Hemoglobin level, g/dl Continuousα .230 0.95 (0.87–1.04) .513 0.96 (0.86–1.08)
CD4 lymphocytes count, cells/mm3 Continuous .442 1.00 (0.998–1.004) .906 1.00 (0.997–1.003)
α: These three continuous data had negative coefficient of correlation
* SPP: smear positive pulmonary, SNP: smear negative pulmonary, EP: extra-pulmonary
TB: tuberculosis
doi:10.1371/journal.pone.0132394.t002
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Table 3. Factors associated with death during the intensive phase of tuberculosis treatment with all variables categorized.
Variables Univariate analysis Multivariable analysis
p Odd ratios
(95%CI)
p Adjusted odd ratios
(95%CI)
Sex Male .786 0.94 (0.62–1.43) .196 0.67 (0.36–1.23)
Female 1
Age, years 20–34 .241 1.01 (0.99–1.03) .600 0.83 (0.40–1.69)
35–49 .763 1.07 (0.69–1.67) .758 0.90 (0.45–1.80)
50 and more 1
Level of education Primary/No formal .763 1.07 (0.69–1.67) .997 1.00 (0.59–1.70)
Secondary/Tertiary 1
Marital status Alone (single/widowed/ divorced) .913 0.97 (0.64–1.50) .784 1.09 (0.58–2.06)
Married/Cohabitating 1
Area of residence Rural .111 1.65 (0.89–3.04) .321 1.50 (0.67–3.36)
Urban 1
Year of TB diagnosis 2006–2009 .657 1.11 (0.70–1.77) .791 1.09 (0.57–2.11)
2010–2013 1
Clinical presentation* SPP TB only 1
SNP TB only .749 1.11 (0.60–2.04) .095 1.97 (0.89–4.36)
EP TB only .018 1.84 (1.11–3.05) .017 2.19 (1.51–4.17)
Mixed (Pulmonary + EP TB) .644 0.81 (0.33–1.97) .875 1.09 (0.39–3.06)
Status at TB diagnosis New .942 0.98 (0.52–1.84)
Retreatment 1 .336 1.47 (0.67–3.196)
Duration of know HIV infection, years < 1 1
 1 .394 0.76 (0.40–1.43) .186 0.56 (0.24–1.31)
Body weight, Kg < 50 .939 1.02 (0.67–1.56) .727 1.10 (0.65–1.84)
 50 1
Presence of another AIDS opportunistic infection Yes .196 0.73 (0.45–1.18) .304 1.37 (0.75–2.47)
No 1
Presence of non-AIDS comorbidity Yes .027 1.85 (1.07–3.20)
No 1 .023 2.23 (1.12–4.46)
Cotrimoxazole prophylactic therapy Yes 1
No .363 0.81 (0.52–1.27) .769 1.09 (0.62–1.92)
Antiretroviral therapy Yes 1
No .899 1.03 (0.67–1.58) .125 0.65 (0.38–1.13)
White blood cell count, cells/mm3 < 4.000 .530 0.86 (0.54–1.37) .712 0.90 (0.52–1.56)
> 10.000 .672 1.14 (0.62–2.11) .982 0.99 (0.47–2.09)
4.000–10.000 1
Hemoglobin level, g/dl < 8 .800 1.06 (0.69–1.62) .565 0.86 (0.51–1.45)
 8 1
CD4 lymphocytes count, cells/mm3 < 50 .434 0.72 (0.31–1.64) .552 0.74 (0.27–2.03)
50–199 .477 0.73 (0.31–1.74) .346 0.60 (0.21–1.74)
 200 1
* SPP: smear positive pulmonary, SNP: smear negative pulmonary, EP: extra-pulmonary
TB: tuberculosis
doi:10.1371/journal.pone.0132394.t003
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2012. Prior to 2012, it was recommended that ART therapy in the setting of HIV be started
when the CD4 cell count dropped to less than 200 cells/mm3; the 2012 revision instead advised
prescribing ART once the CD4 cell count reached 350 cells/mm3. This likely lead to more of
our patients being started on ART later in the study period; tuberculosis guidelines however,
remained unchanged for the entire period of our study. Some data for body weight, hemoglo-
bin level, white blood cell count, and CD4 count were missing. However, multiple imputations
have been used to handle the missing data. Whatever the underlying cause, the missing data
underscores the challenges of conducting “real-life” clinical research in resource-limited set-
tings, like Cameroon and other sub-Saharan countries. Our results may, therefore, not be gen-
eralizable to all patients with TB/HIV, and particularly to those receiving their treatment on an
ambulatory basis. After starting treatment in hospital, patients continued their TB as outpa-
tients; it is thus possible that we underestimated the actual overall death rate as some patients
were lost to follow-up. This study thus provides at least a conservative assessment of mortality
while providing knowledge of risks and preliminary information to guide future research.
Conclusions
In our setting, among patients co-infected with TB and HIV undergoing TB treatment, the
incidence of death during intensive phase of TB treatment was high. The independent factors
associated with mortality during intensive of TB treatment were easily identifiable clinical
ones, having extra-pulmonary TB and having non-AIDS comorbidity. Timely consideration
and identification of extra-pulmonary TB can help to reduce early death by allowing for
prompt initiation of TB treatment at a relatively earlier stage of immunosuppression. Treat-
ment of non-AIDS comorbidities and optimal control of chronic ones, along with reduction in
the amount of medications prescribed in order to include only essential pills are straightfor-
ward measures that may help to reduce early death. Further studies focused on mortality dur-
ing initial TB treatment are needed and should include investigation into the causes of death in
order to better determine if early deaths are due to inadequate TB control, or to other processes
including, but not limited to drug toxicities, IRIS, or worsening of comorbid illnesses.
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